Fiche publication
Date publication
août 2026
Journal
European heart journal. Quality of care & clinical outcomes
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Hosseini K, Girerd N, Roubille F, Monzo L, Baudry G, Epstein J, Guillemin F, Boivin JM
Lien Pubmed
Résumé
Tafamidis has been demonstrated to improve survival and quality of life in transthyretin amyloid cardiomyopathy (ATTR-CM). However, its cost-effectiveness has been reported to exceed the threshold of $100,000/quality-adjusted life years [QALY] in the US healthcare system. This study aimed to evaluate costs associated with utilities (QALYs) gained for ATTR-CM in France, Spain, Germany, and the United Kingdom (UK), and to conduct a deterministic modelling study using case-scenarii based on various assumptions at a European level.
Mots clés
Cardiac amyloidosis, Cost-effectiveness, QALY, TTR stabilizer, Transthyretin, Treatment
Référence
Eur Heart J Qual Care Clin Outcomes. 2026 08 18;:
